SAN DIEGO, October 04, 2022–(BUSINESS WIRE)–Lyme disease is the fastest-growing vector-borne disease in the United States, and its increased prevalence is challenging the scientific community to look for new ways to diagnose and treat this worrisome infection. One answer is found in the discovery of novel drugs; and the breakthrough efforts taking place in this arena are the subject of a new webinar made available by Quidel Corporation, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions.
The 90-minute webinar, available free at https://education.quidel.com/category/lyme-disease, will explain what a small molecule drug is and how it works, identify the methods used to unearth a new drug by high-throughput screening, and discuss how to recognize the complexities involved in developing a new drug for infectious disease in general. It will also provide an overview as to the current antibiotics used for treating Lyme disease and explore how powerful new drugs—novel inhibitors—can selectively target Borrelia burgdorferi (the bacterium that causes Lyme disease). The webinar is PACE-accredited and sponsored in collaboration with Global Lyme Alliance.
Conducting the webinar is Timothy Haystead, Ph.D., professor of pharmacology and cancer biology at Duke University School of Medicine. Dr. Haystead’s current research is focused on the use of chemical biology approaches to define novel drug targets. These drug targets are focused on the treatment of hypertension, obesity, cancer, inflammatory and infectious disease. Dr. Haystead received his Ph.D. from the University of Dundee, Scotland; and he completed post-doctoral work in pharmacology at the Howard Hughes Medical Institute, University of Washington, Seattle.
The new webinar is the latest in an ongoing series sponsored by Quidel that has featured noted scientists, researchers and physicians discussing issues surrounding the prevalence of Lyme disease in America, including ways to reduce the chances of infection, early detection and treatment options. The timing and relevance for these webinars is particularly important as Lyme disease is on the rise to record numbers with approximately 476,000 new cases annually in the United States alone.
Quidel is the diagnostic health care manufacturer behind the industry’s most rapid and reliable in-office test for Lyme disease, Sofia® 2 Lyme FIA. It is the only FDA-cleared rapid point-of-care test on the market, which provides the patient and physician with indicative results in as few as three minutes, as opposed to days, which has historically been the norm (and during which time organisms can spread and become systemic). It can be performed in the privacy of a doctor’s office or local clinic; and it is the only test that can get results from a simple finger prick of blood.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005339/en/
breakwhitelight (for Quidel Corporation)
Regeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Biogen (NASDAQ: BIIB) are developing remarkable therapies that, instead of merely treating disorders, have the potential to cure them or at least make an impact that no other drug has to date. The reason that's not a big cause for alarm is that the company's second-quarter revenue of $2.86 billion would be up 20% over the same period in 2021 if its COVID-19 therapy, REGEN-COV, was excluded from total revenue. The company's sales of the treatment ended late last year when government contracts for the therapy ended.
AstraZeneca Rare Disease, the local division formed when the British pharma giant acquired Alexion Pharmaceuticals Inc. last year, has scooped up a struggling local biotech at a significant premium. AstraZeneca plc (Nasdaq: AZN) is buying LogicBio Therapeutics Inc. (Nasdaq: LOGC) for $2.07 per share, a 660% premium that values the total acquisition at $68 million. Lexington-based LogicBio has been struggling since February, when the U.S. Food and Drug Administration ordered a halt to an early-stage trial testing a drug in pediatric patients with methylmalonic acidemia, a disorder in which the body cannot break down certain proteins and fats.
KalVista Pharmaceuticals Inc. shares tumbled 47% in premarket trade Tuesday, after the company said it's halting a Phase 2 trial of a treatment for hereditary angioedema, after multiple patients showed liver enzyme elevations. No patients had concomitant elevation of bilirubin levels and all were asymptomatic, the company said in a statement. "We made the difficult decision to terminate KOMPLETE because we concluded that the emerging safety profile of the current formulation will not meet our re
Kalvista Pharmaceuticals scrapped an experimental hereditary angioedema drug on Tuesday due to safety issues, and the biotech stock tumbled.
Apellis and Belite Bio were among the worst-performing biotech stocks Monday after presenting test results in two eye diseases.
Eli Lilly (NYSE: LLY) was already having a great year in the stock market, but on Sept. 28, the company's shares jumped by about 7%. The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab. Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too.
Hall of Fame quarterback Terry Bradshaw said Sunday he has been treated for two forms of cancer in the past year. Bradshaw said on “Fox NFL Sunday” that he was diagnosed with bladder cancer late last year and was treated at Yale University Medical Center, including surgery. “As of today, I am bladder cancer free,” Bradshaw said.
On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia. With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug. Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.
AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.
Quest Diagnostics in its latest media report notes that demand for COVID-19 molecular diagnostic testing declined in August compared to the prior month.
Reata Pharmaceuticals (RETA) is yet to generate product revenues due to the lack of marketed drugs in its portfolio. However, two of its pipeline candidates are close to potential FDA approval.
Sneaky food additives are everywhere in our food system, and condiments are one of the biggest culprits. If you're watching your blood sugar, you'll want to check your dressings for large amounts of added sugars, carbohydrates, and unhealthy fats.Checking nutrition labels is one of the easiest ways to spot added sugars in the diet. The new, updated nutrition labels now make it easier than ever with an "added sugar" line on the nutrition facts to decipher exactly how much of the sugar is naturall
'A lot of passengers on cruises fall into high-risk groups, and medical care and evacuation are challenging,' said the University of Utah's Andrew Pavia.
Check your refrigerators!
For every 2,000 steps you take each day, your risk for premature death may fall by 8 to 11 percent, according to research published in the journal JAMA Internal Medicine. Along with the results from a related study, published in JAMA Neurology, the researchers also found that walking more, accumulating up to roughly 10,000 steps a day, was linked to a reduction in the occurrence of cardiovascular disease (including heart disease, stroke and heart failure), 13 types of cancer and dementia.Subscri
As a new study confirms drinking too much really does make you look older, Lisa Salmon looks into other lifestyle factors that may contribute too
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.
Wilmington biotech company Incyte has agreed to acquire Villaris Therapeutics in a deal valued at up to $1.36 billion. The centerpiece of the deal is auremolimab, a monoclonal antibody that is under development to treat the skin disorder vitiligo — but has potential applications beyond dermatology. Villaris, based in Cary, North Carolina, was founded in 2019 and is backed by Medicxi, a health care-focused investment firm based in London.
Shares of Calithera Biosciences Inc. jumped 14.6% in premarket trading on Monday after the company said it received a Fast Track designation for its experimental treatment for non-small cell lung cancer. The drug is currently being tested in Phase 2 clinical trial. Calithera's stock has tumbled 77.9% so far this year, while the S&P 500 has declined 24.7%.
Amylyx Pharmaceuticals' co-founders have said they want to use their newfound platform to bring down barriers to ALS care.